7.46 USD
+0.41 (+5.82%)
7.5281 USD
+0.07 (+0.91%)
We assign a fundamental rating of 3 out of 10 to WVE. WVE was compared to 192 industry peers in the Pharmaceuticals industry. WVE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. WVE is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year WVE has reported negative net income.
WVE had a negative operating cash flow in the past year.
WVE had negative earnings in each of the past 5 years.
WVE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
WVE has a Return On Assets of -50.63%. This is in the lower half of the industry: WVE underperforms 61.98% of its industry peers.
Looking at the Return On Equity, with a value of -92.28%, WVE is in line with its industry, outperforming 41.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.63% | ||
| ROE | -92.28% | ||
| ROIC | N/A |
ROA(3y)-53%
ROA(5y)-54.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for WVE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
WVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
WVE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, WVE has more shares outstanding
WVE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -1.60, we must say that WVE is in the distress zone and has some risk of bankruptcy.
WVE has a Altman-Z score (-1.60) which is comparable to the rest of the industry.
There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.6 |
ROIC/WACCN/A
WACC8.89%
2.3 Liquidity
A Current Ratio of 2.51 indicates that WVE has no problem at all paying its short term obligations.
With a Current ratio value of 2.51, WVE perfoms like the industry average, outperforming 44.79% of the companies in the same industry.
WVE has a Quick Ratio of 2.51. This indicates that WVE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.51, WVE is in line with its industry, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.51 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 32.43% over the past year.
The Revenue has grown by 103.75% in the past year. This is a very strong growth!
WVE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 46.63% yearly.
EPS 1Y (TTM)32.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.91%
Revenue 1Y (TTM)103.75%
Revenue growth 3Y38.28%
Revenue growth 5Y46.63%
Sales Q2Q%199.11%
3.2 Future
WVE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.84% yearly.
WVE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 44.69% yearly.
EPS Next Y-48.65%
EPS Next 2Y-23.26%
EPS Next 3Y-1.63%
EPS Next 5Y19.84%
Revenue Next Year-12.14%
Revenue Next 2Y-3.39%
Revenue Next 3Y35.66%
Revenue Next 5Y44.69%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
WVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year WVE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.26%
EPS Next 3Y-1.63%
5. Dividend
5.1 Amount
WVE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.46
+0.41 (+5.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners87.06%
Inst Owner Change3.33%
Ins Owners0.48%
Ins Owner Change-2.07%
Market Cap1.19B
Revenue(TTM)109.23M
Net Income(TTM)-122.20M
Analysts84
Price Target20.34 (172.65%)
Short Float %9.97%
Short Ratio4.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.92%
Min EPS beat(2)-6.2%
Max EPS beat(2)-5.63%
EPS beat(4)1
Avg EPS beat(4)42.65%
Min EPS beat(4)-10.05%
Max EPS beat(4)192.48%
EPS beat(8)2
Avg EPS beat(8)13.75%
EPS beat(12)4
Avg EPS beat(12)-24.39%
EPS beat(16)5
Avg EPS beat(16)-19.89%
Revenue beat(2)0
Avg Revenue beat(2)-24.9%
Min Revenue beat(2)-32.32%
Max Revenue beat(2)-17.49%
Revenue beat(4)1
Avg Revenue beat(4)30.06%
Min Revenue beat(4)-32.32%
Max Revenue beat(4)195.76%
Revenue beat(8)2
Avg Revenue beat(8)-5.69%
Revenue beat(12)4
Avg Revenue beat(12)7.93%
Revenue beat(16)4
Avg Revenue beat(16)-14.72%
PT rev (1m)1.5%
PT rev (3m)-0.97%
EPS NQ rev (1m)-0.73%
EPS NQ rev (3m)-6.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.92%
Revenue NQ rev (1m)-11.27%
Revenue NQ rev (3m)-19.41%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-4.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 10.87 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.97 | ||
| P/tB | 8.97 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.75
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0.69
BVpS0.83
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.63% | ||
| ROE | -92.28% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-53%
ROA(5y)-54.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 23.07% | ||
| Cap/Sales | 0.74% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.51 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | -1.6 |
F-Score4
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)22.36%
Cap/Depr(5y)18.22%
Cap/Sales(3y)13.04%
Cap/Sales(5y)9.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.91%
EPS Next Y-48.65%
EPS Next 2Y-23.26%
EPS Next 3Y-1.63%
EPS Next 5Y19.84%
Revenue 1Y (TTM)103.75%
Revenue growth 3Y38.28%
Revenue growth 5Y46.63%
Sales Q2Q%199.11%
Revenue Next Year-12.14%
Revenue Next 2Y-3.39%
Revenue Next 3Y35.66%
Revenue Next 5Y44.69%
EBIT growth 1Y10.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.48%
EBIT Next 3Y-13.06%
EBIT Next 5YN/A
FCF growth 1Y-864.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-907.22%
OCF growth 3YN/A
OCF growth 5YN/A
WAVE LIFE SCIENCES LTD / WVE FAQ
What is the ChartMill fundamental rating of WAVE LIFE SCIENCES LTD (WVE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to WVE.
What is the valuation status of WAVE LIFE SCIENCES LTD (WVE) stock?
ChartMill assigns a valuation rating of 0 / 10 to WAVE LIFE SCIENCES LTD (WVE). This can be considered as Overvalued.
Can you provide the profitability details for WAVE LIFE SCIENCES LTD?
WAVE LIFE SCIENCES LTD (WVE) has a profitability rating of 0 / 10.
What is the earnings growth outlook for WAVE LIFE SCIENCES LTD?
The Earnings per Share (EPS) of WAVE LIFE SCIENCES LTD (WVE) is expected to decline by -48.65% in the next year.